- Email: [email protected]
Preliminary results of a quality assurance network for radiotherapy centres in Europe
Medical Dosimetry, Vol. 19, No. 3, pp. 187-191, 1994 1994 American Association of Medical Dosimetrists Printed in the USA. All rights reserved 0958-3947194 $6.00 + .OO
Pergamon
l
Selected Abstracts From the Journal Radiotherapy and Oncology “Europe Against Cancer”, has been set up in 1991 for European centres, not involved in clinical research. Besides a survey of radiotherapy infrastructure, the project includes three measurement steps: primarily a check of beam output and quality in reference conditions with a mailed TLD-procedure, in a second step the mailed verification of other beam data and dose calculation procedures with a multipurpose phantom and finally in vivo dosimetry at the individual patient levels with mailed dosimeters. The results of infrastructure show good agreement with the data previously published by EORTC for research centres. Until January 1993, a total number of 37 centres (49 X-ray beams and 28 cobalt beams) from Belgium, France, Italy, The Netberlands, Sweden and The Czech and Slovak Republics have participated in the first measurement step. Deviations >3% and <6% from the stated dose are found in 17 out of the 79 checked beams. A deviation <6% from the stated dose is detected in only 1 out of the 28 cobalt beams, but in 7 of the 49 X-ray beams. The large majority of the beams (231 25) with deviations >3% belong to centres not having participated in external audits in the previous 5 years. A pilot study for the second step shows larger deviations in non reference conditions, especially for off-axis points and for oblique phantom surface. The third step has yet to be implemented. The initial stage of the project already demonstrates the usefulness of the programme especially for centres which have never before participated in external audits. Four more countries will join the programme and more centres are volunteering to participate than can be measured. A minimal central structure for the programme guarantees uniformity of procedures, interchangeable information, follow-up and joint resolution of specific technical problems. committee
MAILED TL DOSIMETRY PROGRAMME FOR MACHINE OUTPUT CHECK AND CLINICAL APPLICATION IN THE EORTC RADIOTHERAPY GROUP U. Hansson:
K. A. Johansson,2 J. C. Horiot,b J. Bemief
“Radiation Physics Department, University of Gothenburg, Sahlgren Hospital, Gothenburg, Sweden, bCentre G. F. Leclerc, 1 Rue du Prof. Marlon, Dijon, France, ‘Ospedale San Giovanni, Bellizona, Switzerland Vol. 29, 1993, pp. 85-90 Key words: TL dosimetry; Quality assurance; Mailed
dosimetry The Radiotherapy group of the European Organisation for Research and Treatment of Cancer (EORTC-RT) has been performing quality assurance with mailed TL dosimetxy since 1986. The programme consists of therapy machine output checks, in vivo measurements, and dosimetry for brachytherapy. The therapy machine output checks have revealed a few large deviations (greater than 7%) between EORTC-measured and institute-stated dose, but also shown an improvement in the dosimetry of the participating institutes as a result of consecutive mailings. The use of in vivo dosimetry with mailed TLD has proven that it is feasible to detect deviations of 25%. The results have shown deviations within 25% for dosimeters located well within the radiation field for internal measurements in the pelvic region. Dosimetry of brachytberapy has been performed for low dose rate ‘921rsources. Differences of 14% can be seen between the participating centres. SSDI 0167-8140(93)01265-Q
SSDI 0167-8140(93)01260-V
PRELIMINARY RESULTS OF A QUALITY ASSURANCE NETWORK FOR RADIOTHERAPY CENTRES IN EUROPE
MEASUREMENT POSSIBILITIES USING AN ELECTRONIC PORTAL IMAGING DEVICE M. C. Kirby, P. C. Williams
A. Dutreix,” E. van der Schueren,” S. Derreumaux,b J. Chavaudrab
North Western Medical Physics Department, Christie Hospital, Manchester M20 9BX, UK
“Radiotherapy Department, University Hospital, Capucijnenvoer 33, 3000 Leuven, Belgium, bPhysics Department, Institut Gustave Roussy, 94805 Villejuif, Cedex, France
Vol. 29, 1993, pp. 237-243 Key words: Portal imaging; Exit dosimetry; Quality
Vol. 29, 1993, pp. 97-101
control; Multileaf collimator
Key words: Quality Assurance; Dosimetry
A vital role in the quality control of radiotherapy is the use of portal imaging for verifying field size, shape, orientation and patient set-up. Coincidence of treated volume and target volume is imperative. Electronic portal imaging devices are effective at providing this verification. However, these devices are versatile enough to be used in other ways pertinent to the delivery of high quality, high precision radiotherapy. This paper examines two such ways: in assessing the reproducibility of a multileaf collimator system, and in determining exit doses in vivo. Configured as a dosemeter, the system
intercomparison; Dosimetry networks; Radiotherapy infrastructure; Mailed dosimetry Based on the IAEA/WHO experience in mailed dosimetry, a Quality Assurance (QA) Network, sponsored by the EC Selected Abstracts-designed to keep readers up to date by providing original abstracts of current literature from Rudioherapy and Oncology, an Elsevier Science Ltd journal. 187
Pergamon
l
Selected Abstracts From the Journal Radiotherapy and Oncology “Europe Against Cancer”, has been set up in 1991 for European centres, not involved in clinical research. Besides a survey of radiotherapy infrastructure, the project includes three measurement steps: primarily a check of beam output and quality in reference conditions with a mailed TLD-procedure, in a second step the mailed verification of other beam data and dose calculation procedures with a multipurpose phantom and finally in vivo dosimetry at the individual patient levels with mailed dosimeters. The results of infrastructure show good agreement with the data previously published by EORTC for research centres. Until January 1993, a total number of 37 centres (49 X-ray beams and 28 cobalt beams) from Belgium, France, Italy, The Netberlands, Sweden and The Czech and Slovak Republics have participated in the first measurement step. Deviations >3% and <6% from the stated dose are found in 17 out of the 79 checked beams. A deviation <6% from the stated dose is detected in only 1 out of the 28 cobalt beams, but in 7 of the 49 X-ray beams. The large majority of the beams (231 25) with deviations >3% belong to centres not having participated in external audits in the previous 5 years. A pilot study for the second step shows larger deviations in non reference conditions, especially for off-axis points and for oblique phantom surface. The third step has yet to be implemented. The initial stage of the project already demonstrates the usefulness of the programme especially for centres which have never before participated in external audits. Four more countries will join the programme and more centres are volunteering to participate than can be measured. A minimal central structure for the programme guarantees uniformity of procedures, interchangeable information, follow-up and joint resolution of specific technical problems. committee
MAILED TL DOSIMETRY PROGRAMME FOR MACHINE OUTPUT CHECK AND CLINICAL APPLICATION IN THE EORTC RADIOTHERAPY GROUP U. Hansson:
K. A. Johansson,2 J. C. Horiot,b J. Bemief
“Radiation Physics Department, University of Gothenburg, Sahlgren Hospital, Gothenburg, Sweden, bCentre G. F. Leclerc, 1 Rue du Prof. Marlon, Dijon, France, ‘Ospedale San Giovanni, Bellizona, Switzerland Vol. 29, 1993, pp. 85-90 Key words: TL dosimetry; Quality assurance; Mailed
dosimetry The Radiotherapy group of the European Organisation for Research and Treatment of Cancer (EORTC-RT) has been performing quality assurance with mailed TL dosimetxy since 1986. The programme consists of therapy machine output checks, in vivo measurements, and dosimetry for brachytherapy. The therapy machine output checks have revealed a few large deviations (greater than 7%) between EORTC-measured and institute-stated dose, but also shown an improvement in the dosimetry of the participating institutes as a result of consecutive mailings. The use of in vivo dosimetry with mailed TLD has proven that it is feasible to detect deviations of 25%. The results have shown deviations within 25% for dosimeters located well within the radiation field for internal measurements in the pelvic region. Dosimetry of brachytberapy has been performed for low dose rate ‘921rsources. Differences of 14% can be seen between the participating centres. SSDI 0167-8140(93)01265-Q
SSDI 0167-8140(93)01260-V
PRELIMINARY RESULTS OF A QUALITY ASSURANCE NETWORK FOR RADIOTHERAPY CENTRES IN EUROPE
MEASUREMENT POSSIBILITIES USING AN ELECTRONIC PORTAL IMAGING DEVICE M. C. Kirby, P. C. Williams
A. Dutreix,” E. van der Schueren,” S. Derreumaux,b J. Chavaudrab
North Western Medical Physics Department, Christie Hospital, Manchester M20 9BX, UK
“Radiotherapy Department, University Hospital, Capucijnenvoer 33, 3000 Leuven, Belgium, bPhysics Department, Institut Gustave Roussy, 94805 Villejuif, Cedex, France
Vol. 29, 1993, pp. 237-243 Key words: Portal imaging; Exit dosimetry; Quality
Vol. 29, 1993, pp. 97-101
control; Multileaf collimator
Key words: Quality Assurance; Dosimetry
A vital role in the quality control of radiotherapy is the use of portal imaging for verifying field size, shape, orientation and patient set-up. Coincidence of treated volume and target volume is imperative. Electronic portal imaging devices are effective at providing this verification. However, these devices are versatile enough to be used in other ways pertinent to the delivery of high quality, high precision radiotherapy. This paper examines two such ways: in assessing the reproducibility of a multileaf collimator system, and in determining exit doses in vivo. Configured as a dosemeter, the system
intercomparison; Dosimetry networks; Radiotherapy infrastructure; Mailed dosimetry Based on the IAEA/WHO experience in mailed dosimetry, a Quality Assurance (QA) Network, sponsored by the EC Selected Abstracts-designed to keep readers up to date by providing original abstracts of current literature from Rudioherapy and Oncology, an Elsevier Science Ltd journal. 187